EnovisENOV +2.95%61 EV-to-FCF is 73.69 as of Jun. 25, 2026, which is 232% above its 10-year median of 22.21. GuruFocus rates ENOV with a GF Score™ of 61/100 and a GF Value™ of $49.60 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 420 Medical Devices & Instruments companies, Enovis ranks worse than 82.14% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Enovis's Enterprise Value is $2,647 Mil.
Enovis's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $36 Mil. Therefore, Enovis's EV-to-FCF for today is 73.69.
The historical rank and industry rank for Enovis's EV-to-FCF or its related term are showing as below:
ENOV'
s EV-to-FCF Range Over the Past 10 Years
Min: -852.15 Med: 22.21 Max: 1001.94
Current: 73.69
During the past 13 years, the highest EV-to-FCF of Enovis was 1001.94. The lowest was -852.15. And the median was 22.21.
ENOV's EV-to-FCF is ranked worse than 82.14% of 420
companies
in the Medical Devices & Instruments industry
Industry Median: 22.865
vs ENOV: 73.69
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-06-25), Enovis's stock price is $22.01.
Enovis's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-19.880. Therefore, Enovis's PE Ratio (TTM) for today is At Loss.
Enovis (NYSE:ENOV) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Enovis's share price for today is $22.01.
Enovis's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-19.880.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Enovis EV-to-FCF Related Terms
Enovis EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Enovis's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Enovis's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Enovis EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Enovis's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Enovis's EV-to-FCF falls into.
Enovis's current Enterprise Value is $2,647 Mil.
Enovis's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $36 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enovis (ENOV) has a EV-to-FCF of 73.69 as of Jun. 25, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Enovis and its competitors. This is 232% above median its historical median of 22.21. According to the industry distribution chart, Enovis ranks #345 out of 420 companies in the Medical Devices & Instruments industry, placing it in the top 82.1%.
Is Enovis' EV-to-FCF too high?
Enovis' current EV-to-FCF of 73.69 is 232% above median its 10-year median of 22.21. The Medical Devices & Instruments industry median EV-to-FCF is 22.87. Enovis' value of 73.69 is 222.3% above this industry median. Based on the distribution chart, Enovis ranks #345 out of 420 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Enovis has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Enovis' EV-to-FCF compare to IART and AHCO?
According to the Medical Devices & Instruments industry distribution chart, Enovis ranks #345 out of 420 companies for EV-to-FCF. This places Enovis in the lower half of its industry. The industry median EV-to-FCF is 22.87. Enovis' value of 73.69 is 222.3% above this benchmark. While the company's 10-year median is 22.21 vs. the industry median of 22.87, Enovis has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 22.87, based on 420 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Enovis's current EV-to-FCF of 73.69 is 222.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Enovis and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 22.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Enovis's current EV-to-FCF is 73.69, which is 232% above median its own 10-year median of 22.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enovis stock overvalued right now?
Based on GuruFocus' analysis, Enovis (ENOV) is currently considered Possible Value Trap. The stock's GF Value™ is $49.60, compared to a current price of $22.01 — trading 55.6% below its estimated fair value. The current EV-to-FCF is 73.69, which is 232% above median its 10-year median of 22.21 and 222.3% above the Medical Devices & Instruments industry median of 22.87. Enovis' overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Enovis (ENOV), the current EV-to-FCF is 73.69 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Enovis (ENOV) Overvalued in 2026?
Based on GuruFocus' analysis, Enovis stock appears to be undervalued.
The current stock price of $22.01 is trading 55.6% below its estimated GF Value™ of $49.60.
GuruFocus considers Enovis to be Possible Value Trap.
Key valuation signals for ENOV:
EV-to-FCF: 73.69 (232% above median its 10-year median of 22.21)
GF Value™: $49.60 vs. price of $22.01 (55.6% below fair value)
Industry Position: 222.3% above the Medical Devices & Instruments median (#345 of 420)
No single metric tells the full story. See the ENOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention through post-surgical or post-injury rehabilitation and treatment of degenerative conditions. The company's reportable segments include Prevention & Recovery and Reconstructive segments. The majority of revenueis derived from the Prevention & Recovery segment, which includes products that are used by orthopedic specialists, primary care physicians, physical therapists, chiropractors, athletic trainers and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformitiesand sports-related injuries.
61GF Score
Get the complete analysis for ENOV
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ENOV has been successfully added to your 
